Note 18 - Segments (Tables)

12 Months Ended

Dec. 31, 2018

Year Ended December 31, 2018	Diagnostics			Therapeutics			Corporate			Total
Royalty revenue	$	15,347		$	—		$	—		$	15,347
License revenue		307,174			—			—			307,174
Grant and other revenue		494,997			351,833			—			846,830
Total revenue		817,518			351,833			—			1,169,351
Cost of revenue		96,636			—			—			96,636
Research and development expenses		3,064,115			1,157,766			—			4,221,881
Selling, general and administrative expenses, excluding depreciation and amortization (a)		—			78,606			7,469,144			7,547,750
Depreciation and amortization (b)		—			—			150,385			150,385
Loss from operations (c)		(2,343,233	)		(884,539	)		(7,619,529	)		(10,847,301	)
Other expense (d)		—			—			(5,321,270	)		(5,321,270	)
Benefit from income taxes		1,413			534			7,806			9,753
Loss from continuing operations		(2,341,820	)		(884,005	)		(12,932,993	)		(16,158,818	)
Income from discontinued operations, net of tax effect		1,449			—			—			1,449
Gain on sale of discontinued operations, net of tax effect		43,053			—			—			43,053
Net loss		(2,297,318	)		(884,005	)		(12,932,993	)		(16,114,316	)
Total assets, net of depreciation and amortization:
United States	$	91,425			24,763			6,878,129			6,994,317
International		14,330						381			14,711
Capital expenditures		—			—			46,192			46,192

Year Ended December 31, 2017	Diagnostics			Therapeutics			Corporate			Total
Royalty revenue	$	9,126		$	—		$	—		$	9,126
License revenue		100,000			—			—			100,000
Grant and other revenue		1,506,232			195,079			—			1,701,311
Total revenue		1,615,358			195,079			—			1,810,437
Cost of revenue		3,651			—			—			3,651
Research and development expenses, excluding depreciation and amortization		3,784,255			729,587			—			4,513,842
Selling, general and administrative expenses, excluding depreciation and amortization (a)		—			34,484			10,895,301			10,929,785
Depreciation and amortization (b)		—			—			240,166			240,166
Loss from operations (c)		(2,172,548	)		(568,992	)		(11,135,467	)		(13,877,007	)
Other income (expense) (d)		—			—			(3,912,679	)		(3,912,679	)
Benefit from income taxes		496,127			129,936			3,436,426			4,062,489
Loss from continuing operations		(1,676,421	)		(439,056	)		(11,611,720	)		(13,727,197	)
Income from discontinued operations, net of tax effect		88,673,053			—			—			88,673,053
Net income (loss)		86,996,632			(439,056	)		(11,611,720	)		74,945,856
Total assets, net of depreciation and amortization:
United States	$	13,065,871		$	49,001		$	7,634,237		$	20,749,109
International		30,476			—			1,851			32,327
Capital expenditures		—			—			33,690			33,690